

ACCELERON PHARMA INC  
Form 8-K  
December 09, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **December 9, 2013**

---

**ACCELERON PHARMA INC.**

(Exact name of Registrant as specified in its charter)

**Delaware**

(State or other

jurisdiction of incorporation)

**001-36065**

(Commission File Number)

**27-0072226**

(I.R.S. Employer

Identification Number)

**128 Sidney Street**

**Cambridge, MA**

(Address of principal  
executive offices)

**02139**

(Zip Code)

Edgar Filing: ACCELERON PHARMA INC - Form 8-K

Registrant's telephone number, including area code: **(617) 649-9200**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01 Regulation FD Disclosure.**

On December 9, 2013, Acceleron Pharma Inc. issued a press release announcing that its collaboration partner Celgene reported new interim clinical data at the 2013 American Society of Hematology Annual Meeting. A copy of the press release is furnished as Exhibit 99.1 hereto.

The information contained in this Item, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed filed for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

<b>No.</b>	<b>Description</b>
99.1	Press Release of Acceleron Pharma Inc. dated December 9, 2013.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACCELERON PHARMA INC.

By: */s/ John Quisel, Ph.D., Esq.*  
John Quisel, Ph.D., Esq.  
General Counsel, Vice President and Secretary

Date: December 9, 2013

**EXHIBIT INDEX**

**Exhibits.**

<b>No.</b>	<b>Description</b>
99.1	Press Release of Acceleron Pharma Inc. dated December 9, 2013.